Pharmacological therapy in neuropathic bladder

Pediatric Neurogenic Bladder Dysfunction: Diagnosis, Treatment, Long-Term Follow-up

Volumn , Issue , 2006, Pages 169-183

  Pereira, Pedro López ^a   Urrutia, Maria Jose Martínez ^a   Jaureguizar, Enrique ^a  

^a HOSPITAL INFANTIL LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885163477     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-30867-9_21     Document Type: Chapter

References (156)

1. Abrams P, Amarenco G, Bakke A. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170: 1242-51.
2. Abrams P, Feenan R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
3. Altaweel W, Corcos J, Robichaud C. Botulinum-A toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomenigocele. Eur Urol 2004; 3 (Suppl 3):A671.
4. Alloussi S, Laval K-U, Eckert, et al. Trospium chloride (Spasmoyt) in patients with motor urge syndrome (detrusor instability): A double-blind, randomised, multicentre, placebo-controlled study. J Clin Res 1988; 1:439.
5. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998; 34: 148-53.
6. Amark P, Nergardh A. Influence of adrenergic agonist and antagonist on urethral pressure, bladder pressure and detrusor hyperactivity in children with myelodysplasia. Acta Paed Scand 1991; 80: 824.
7. Anderson RU, Mobley D, Blank B. Once daily controlled versus immediate release oxybutynin chloride for urge incontinence. J Urol 1999; 161: 1809-14.
8. Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35:477-86.
9. Andersson KE. Pharmacology of the lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-62.
10. Andersson KE. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol 1999; 201: 67-72..
11. Andersson KE. Treatment of overactive bladder: Other drug mechanisms. Urology 2000; 55(5A): 51-7.
12. Antweiler H, Lauterbach F, Lehmenn, H D, et al. Pharmakol-ogie and Toxikologie von Azoniaspiranen in der Nortropin-bzw, Pseudonortropin-Reihe. Arzneimittel Forsch Drug Res 1966; 16: 1581.
13. Aoki KR. Pharmacology and immunology of botulinum toxin type A serotypes. Clin Dermatol 2003; 21: 476-80.
14. Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50 (Suppl GA):90-6.
15. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-47.
16. Austin PF, Homsy YL, Masel JL, et al. Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol 1999; 162: 1064-7.
17. Awad SA, Downie JW, Kiriluta HG. Alpha-adrenergic agents in urinary disorders of the proximal urethra, part I : sphinc-teric incontinence. Br J Urol 1978; 50: 332.
18. Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterization. Br J Urol 1990; 66: 532-34.
19. Batinic D, Murtz G, Martin F, et al. Efficacy and tolerability of propiverine in children suffering from overactive bladder: A double-blind, randomized, clinical trial versus oxybutynin and placebo. ICCS and APAPU Joint Meeting, Hong Kong, China, December 2002; 10-13.
20. Bauer S. An approach to neurogenic bladder: An overview: Prob Urol 1994;8:441.
21. Beck R, Amausch T, King C. Results in testing 210 patients with detrusor overactivity incontinence of urine. Am J Obstet Gynecol 1976; 125: 593-97.
22. Bennett BC, Kruse MN, Roppolo JR. Neural control of urethral outlet activity in vivo: role of nitric oxide. J Urol 1995; 153: 2004-9.
23. Bolduc S, Upadhyay J, Payton J, et al. The use of tolterodine in children after oxybutynin failure. BJU Int 2003; 91: 398-401.
24. Bridgewater M, MacNeil HF, Brading AF. Regulation of tone in pig urethral smooth muscle. J Urol 1993; 150: 223-28.
25. Brin MF. Botulinum toxin, chemistry, pharmacology, toxicity and immunology. Muscle Nerve suppl 1997; 6: 5146-68.
26. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al. (eds): Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. NewYork, McGraw-Hill, 1996, pp 141-160.
27. Bultitude M, Hills N, Shuttleworth K, et al. Clinical and experimental studies on the action of prostaglandins and their synthesis inhibitors on detrusor muscle in vitro and in vivo. Br J Urol 1976;48:631-37.
28. Cain MP, Wu SD, Austin PF, et al. Alpha blocker therapy for children with dysfunctional voiding and urinary retention. J Urol 2003; 170: 1514-17.
29. Cardozo L, Chappie C R, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind, multicentre clinical trial. Br. J. Urol 2000; 85: 659.
30. Castelden CM, George CF, Renwick AG, et al. Imipramine: A possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981; 125: 218-21.
31. Caulfield MP, Birdsall N. International Union of Pharmacology: XVI. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90.
32. Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Rail TW, Nies AS, Taylor P (eds): Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York, Pergamon, 1990, pp 463-484.
33. Chancellor MB, Yoshimura N. Physiology and pharmacology of the bladder and urethra. In: Walsh PC, Retik AB, Vaughan ED (eds) Campbell's urology (CD-ROM), 8th edn, Chapter 23, Philadelphia, Saunders, 2003.
34. Chappie CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55(5A): 33-46.
35. Chappie CR, Arano P, Bosch JLHR, et al. Solifenacin appears effective and well tolerated in patients with symtomatic idiopathic detrusor overactivity in a placebo-and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004; 93: 717.
36. Chappie CR, Aubry ML, James S, et al. Characterization of human prostatic adrenoceptors using pharmacology receptor binding and localization. Br J Urol 1989; 63:487-96.
37. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000; 16: 149.
38. Corcos J, Al-Taweel W, Pippi Salle J, et al. The treatment of detrusor hyperreflexia using botulinum A toxin in myelomeningocele patients unresponsive to anticholinergic. Neurou-rol Urodyn 2002; 21: A39.
39. Cruz F, Silva C, Ribeiro M, et al. The effect of intravesical re-siniferatoxin in neurogenic forms of bladder overactivity. Preliminary results of a randomized placebo controlled trial. Neurourol Urodyn 2002: 21 (Suppl 426): 692-97.
40. Danuser H, Thor KB. Inhibition of central sympathetic and somatic outflow to the lower urinary tract of the cat by the al-pha-1 adrenergic receptor antagonist prazosin. J Urol 1995; 153: 1308.
41. Davila GW, Daugherty CA, Saunders SW. A short-term, mul-ticenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140.
42. De Voogt HJ, Van der Sluis C. Preliminary evaluation of al-pha-adrenergic blocking agents in children with neurogenic bladder due to myelomeningocele. Dev Med Child Neurol 1976 (Suppl) 37: 82.
43. Del Popolo G, Li Marzi V, Lombardi G. Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 2004; 3 (Suppl 3): A663.
44. Delhaas EM, Brouwers JR. Intrathecal baclofen overdose: report of 7 events in 5 patients and review of the literature. Int J Clin Pharmacol Uer Toxicol 1991; 29: 274-80.
45. De Seze M, Petit H, Gallien P, et al. Botulinum A toxin and de-trusor-sphincter dyssynergia: A double-blind lidocaine controlled study in 13 patients with spinal cord disease. Eur Urol 2002;42:56-62.
46. Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology 1975; 5: 624.
47. Docherty JR. Subtypes of functional alpha-1 and alpha-2 adrenoceptors. Eur J Pharmacol 1998; 361: 1-15.
48. Doherty MM, Charman WN. The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41: 235.
49. Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. J Urol 2005; 173: 212-6.
50. Drutz H, Appell RA, Gleason DA, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999; 10: 283-89.
51. Dykstra DD, Sidi AA. Treatment of detrusor-striated sphincter dyssynergia with botulinum A toxin. J Urol 1990; 138: 1155-6.
52. Dykstra DD, Sidi A A, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1998; 139: 919-22.
53. Ehren I, Iversen H, Jansson O. Localisation of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 1994; 44: 683-7.
54. Ek A, Andersson K-E, Gullberg B, et al. The effects of long-term treatment with norephinephrine on stress incontinence and urethral closure pressure profile. Scand J Urol Nephrol 1978; 12: 105.
55. Espey MJ, Du H-J, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation. Brain Res 1998; 798: 101-8.
56. Ferrara P, d'Aleo CM, Tarquini E, et al. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 2001; 87: 674-78.
57. Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 1985; 134: 114-16.
58. Fischer C, Diokno A, Lapides J. The anticholinergic effects of dicyclomine hydrochloride in uninhibited neurogenic bladder dysfunction. J Urol 1978; 120: 328-32.
59. Gajewski J, Downie JW, Awad SA. Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter. J Urol 1984; 132: 403-9.
60. Garcia-Pascual A, Costa G, Labadia A. Characterisation of nitric oxide synthase activity in sheep urinary tract: functional implications. Br J Pharmacol 1996; 118: 905-14.
61. Gilja I, Radej M, Kovacic M, et al. Conservative treatment of female stress incontinence with imipramine. J Urol 1984; 132: 909-14.
62. Gleason D, Reilly R, Bottaccini M, et al. The urethral continence zone and its relation to stress incontinence. J Urol 1974; 112:81-7.
63. Goessl C, Knispel HH, Fiedler U, et al. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology 1998; 51: 94-8.
64. Goessl C, Sauter T, Michael T, et al. Efficacy and tolerability of tolterodine in chidren with detrusor hyperreflexia.Urology 2000; 55: 414.
65. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 1991; 146: 532.
66. Grignaffini A, Bazzani F. Intravesicular prostaglandin E2 for the prophylaxis of urinary retention after colpohysterectomy. Int J Med Res 1998; 26: 87-92.
67. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate release oxybutynin. J Clin Pharmacol 1999; 39: 289.
68. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin Pharmacol Ther 1999; 65: 672.
69. Hachen H, Krucker V. Clinical and laboratory assessment of the efficacy of baclofen on urethral sphincter spasticity in patients with traumatic paraplegia. Paraplegia 1977; 18: 229-35.
70. Hackler R, Broecker B, Klein F, et al. A clinical experience with dantrolene sodium for external urinary sphincter hyper-tonicity in spinal cord injured patients. J Urol 1980; 124: 7883.
71. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. Word J Urol 2003; 20: 392.
72. Harada K, Fujimori A. Cliical pharmacology of alpha-lA selective and non-selective alpha-1 blockers. BJU Int 2000; 86 (Suppl 2): 31-5.
73. Harper M, Fowler CJ, Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU Int 2004; 93: 7026.
74. Harrison NW, Whitfield HN, Williams DI. tte place of alpha-blocking drugs in the treatment of children with neuropathic bladder. Urol Int 1977; 32: 224.
75. Hehir M, Fitzpatrick JM. Oxybutynin and the prevention of urinary incontinence in spina bifida. Eur Urol 1985; 11: 25-46.
76. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 1985; 107: 111-7.
77. Hjalmas K, Hellstrom AL, Mogren K, et al. The overactive bladder in children: A potential future indication for tolterodine. BJU Int 2001; 87: 569-74.
78. Ho KM, McMurray G, Branding AF. Nitric oxide synthase in the heterogeneous population of intramural striated muscle fibres of the human membranous urethral sphincter. J Urol 1998; 159: 1091-6.
79. Ho KM, Ny L, McMurray G. Co-localisation of carbon monoxide and nitric oxide synthesizing enzymes in the human urethral sphincter. J Urol 1999; 161: 1968-72.
80. Homsy YL, Nsouli I, Hamburger B, et al. Effects of oxybutynin on vesicoureteral reflux in children. J Urol 1985; 134: 1168-71.
81. Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999; 126: 819-825.
82. Junemann KP, Al Shukri S. Efficacy and tolerability of tros-pium chloride and tolterodine in 234 patients with urge syndrome: A double-blind, placebo-controlled, multicenter clinical trial. Presented at International Continence Society annual meeting, Tampere, 28 August 2000.
83. Kardash S, Hillman ES, Werry J. Efficacy of imipramine in childhood enuresis: A double blind control study with placebo. Can Med Assoc J 1968; 99: 263.
84. Kasabian NG, Bauer SB, Dyro FM, et al. The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am J Dis Child 1992; 146: 840-43.
85. Keast JR, Kawatani M. Extensive distribution ofNADHP di-aphorase activity in the nerve supply of the cat lower urinary tract. Autonom Nerv Syst 1994; 50: 116-69.
86. Kishimoto T, Aoki K, Okimaya Y, et al. Effect of clenbuter-ol on contractile response in periurethral striated muscle of rabbits. J Exp Med 1991; 165: 243-45.
87. Krane R, Olsson C. Phenoxybenzamine in neurogenic bladder dysfunction: I, A theory of micturition. J Urol 1973; 110: 650-4.
88. Kuo HC. Botilinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 2003; 170: 1908-12.
89. Leippold T, Reitz A, Schurch B. Botulinum toxin as new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44: 165-74.
90. Lepor H, Gup DI, Baumann M, et al. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988; 32 (Suppl): 21-6.
91. Levin RM, Wein AJ, Longhurst PA. Neuropharmacology of the lower urinary tract. In: Mundy AR, Stephenson TP, Wein AJ (eds). Urodynamics: principles, practice and application, 2nd edn. Edinburgh: Churchill Livingstone, 1994: 29-41.
92. Lin H-H, Sheu B-C, Lo M-C, et al. Comparison of treatment outcomes of imipramine for female genuine stress incontinence. Br J Obstet Gynecol 1999; 106: 1089-92.
93. Lopez Pereira P, Miguelez C, Caffarati J, et al. Trospium chloride for the treatment of detrusor instability in children. J Urol 2003; 170: 1978-81.
94. Madersbacher H. Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol 2002; 12: 469-72.
95. Madersbacher H, Halaska M, Voight R, et al. A placebo-controlled multicenter study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-65.
96. Madersbacher H, Knoll M. Intravesical application of oxybutynin: mode of action in controlling detrusor-hyperreflexia, preliminary results. Eur Urol 1995; 28: 340-44.
97. Mamas M, Reynard JM, Brading AF. Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury. Lancet 2001; 357: 1964-70.
98. Marschall-Kehrel AD, Murtz G, Kramer G, et al. An empirical treatment algorithm for incontinent children. J Urol 2004; 171: 2667-71.
99. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992; 148: 548.
100. McGuire EJ, Weiss RM. Secondary bladder neck obstruction in patients with urethral valves: Treatment with phenoxybenzamine Urology 1975; 5: 756.
101. Michel MC, Kenny BA, Schwinn DA. Classification of al-pha-1 adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 352:1-10.
102. Michel MC, Schafers RF, Goepel M. Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation? BJU Int 2000; 86 (Suppl 2): 23-30.
103. Mulcahy JJ, James HE, McRoberts JW. Oxybutynin chloride combined with intermittent clean catheterization in the treatment of myelomeningocele patients. J Urol 1977; 118: 95-6.
104. Murdock M, Sax D, Krane R. Use of dantrolene sodium in external sphincter spasm. Urology 1976; 8: 133-8.
105. Newgreen DT, Anderson CWP, Carter AJ, et al. Darifena-cin: A novel bladder-selective agent for urge incontinence. Neurourol Urodyn 1995; 14: 95.
106. Nijman RJM. Classification and treatment of functional incontinence in children, BJU Int 2001; 85(Suppl 3): 37-42.
107. Nijman RJM. Neurogenic and nonneurogenic bladder dysfunction. Curr Opin Urol 2001; 11: 577-83.
108. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine: A new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207.
109. Nishimatsu N, Moriyama N, Hamada K, et al. Contractile responses to alpha-1 adrenoceptor agonists in isolated human male and female urethra. BJU Int 1999; 84: 515-20.
110. Norlen L, Sundin T. Alpha-adrenolitic treatment in patients with autonomous bladders. Acta Pharmacol Toxicol 1978; 43:31.
111. Pannek J, Sommerfeld HJ, Botel U, et al. Combined intravesical and oral oxybutynin chloride in adult patients spinal cord injury. Urolgy 2000; 55: 358.
112. Persson K, Pandita RK, Aszodi A. Functional characteristics or urinary tract smooth muscles in mice lacking cGMP protein kinase type 1. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1112-20.
113. Petit H, Wiart L, Gaujard E, et al. Botulinum A toxin treatment for detruso-sphincter dyssynergia in spinal cord 1998; 36: 91-4.
114. Pinna C, Eberini I, Puglisi L, et al. Presence of constitutive endothelial nitric oxide synthase immunoreactivity in urothelial cells of hamster proximal urethra. Eur J Pharmacol 1999; 367: 85-9.
115. Purcel MH, Gregory JG. Intermittent catheterization, evaluation of complete dryness and independence in children with myelomeningocele. J Urol 1984; 132: 518-20.
116. Raezer DM, Benson GS, Wein AJ, et al. The functional approach to the management of the pediatric neuropathic bladder: A clinical study. J Urol 1977; 117: 649-53.
117. Reitz A, Knapp PA, Muntener M, et al. Oral nitric oxide donors: A new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol 2004; 45:516-20.
118. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-15.
119. Restorick JM, Mundy AR. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol 1989; 63: 32-5.
120. Riccabona M, Koen M, Schindler M, et al. Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004; 171: 845-8..
121. Schulte-Baukloh H, Michael T, Miller K, et al. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int 2002; 90: 716-20.
122. Schulte-Baukloh H, Michael T, Schobert J, et al. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele; preliminary results. Urology 2002; 59: 325-7.
123. Schulte-Baukloh H, Michael T, Sturzbecher B, et al. Botuli-num-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003; 44: 139-43..
124. Schurch B, Hauri D, Rodic B, et al. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023-9.
125. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665..
126. Schurch B, Yasuda K, Rossier AB. Detrusor bladder neck dyssynergia revisited. J Urol 1994; 152: 2066-70.
127. Seiferth J. Types of neurogenic bladder in children with spina bifida and response to treatment with phenoxybenzamine. Dev Med Child Neurol 1977; 37: 94.
128. Seki N, Ikawa S, Pakano N, et al. Intravesical instillation of resiniferatoxin for neurogenic bladder dysfunction in a patient with myelodysplasia. J Urol 2001; 166: 2368-9.
129. Shaffer D, Costello AJ, Hill ID. Control of enuresis with imipramine. Arch Dis Child 1968; 43(232): 665-71.
130. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibres by intravesical resiniferatoxin, a capsaicin analog; long-term results for the treatment of detrusor hyperreflexia: Eur Urol 2000; 38: 444-52.
131. Smet PJ, Jonavicius J, Marshall VR, et al. Distribution of nitric oxide synthase immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996; 71: 337-48.
132. Smith CP, Chancellor MB. Emerging role ofbotulinum toxin in the management of voiding dysfunction. J Urol 2004; 171: 2128-37.
133. Stewart BH, Banowski LHW, Montague DK. Stress incontinence: conservative therapy with sympathomimetic drugs. J Urol 1976; 115: 558.
134. Stockamp K. Treatment with phenoxybenzamine of upper urinary tract complications caused by intravesical obstruction. J Urol 1975; 113: 128.
135. Stohrer M, Madersbacher H, Richter R, et al. Efficacy and safety of propiverine in SCI patients suffering from detrusor hyperreflexia: A double-blind placebo-controlled clinical trial. Spinal Cord 1999; 37: 196-208.
136. Swierzewski SJ, Gormley EA, Belville WD, et al. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol 1994; 151: 951-4.
137. Takeda M, Obara K, Mizusawa T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: Analysis by molecular biological and phar-macological methods. J Pharmacol Exp Ther 1999; 288: 819-825.
138. Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder and enuresis: Urology 1976; 8:452.
139. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813.
140. Thuroff J, Chartier-Kasker E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998; 16 (Suppl 1): 48-61.
141. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57:414.
142. Wein AJ. Pharmacology of incontinence. Urol Clin North Am 1995a; 22: 557-77.
143. Wein AJ. Principles of pharmacologic therapy: Practical drug treatment of voiding dysfunction in the female. In: Raz Wein AJ. Pathophysiology and categorization of voiding dysfunction. In: Walsh PC, Retik AB, Vaughan ED (eds): Campbell's urology (CD-ROM), 8th edn, Chapter 24, Philadelphia, Saunders, 2003.
144. Wein AJ. Neuromuscular dysfunction of the lower urinary tract and its management. In: Walsh PC, Retik AB, Vaughan ED (eds): Campbell's urology (CD-ROM), 8th edn, Chapter 26, Philadelphia, Saunders, 2003.
145. Wein AJ, Barrett DM. Voiding function and dysfunction: A logical and practical approach. Chicago, Year Book Medical, 1988.
146. Wein AJ, Levin RM, Barret DM. Voiding function, relevant anatomy, physiology and pharmacology. In: Gillenwater JY, Grayhack JT, Howards ST, Duckett JW (eds): Adult and pediatric urology, 2nd edn, St. Louis, Mosby, 1991, pp 933-99.
147. Wein AJ, Longhurst PA, Levin RM. Pharmacologic treatment of voiding dysfunction. In: Mundy AR, Stephenson TP, Wein AJ (eds): Urodynamics: principles, practice and application, 2nd edn, Edinburgh, Churchill Livingstone, 1994, pp 43-70.
148. Wein AJ, Monga AK. Applied pharmacology. In: Stanton SL, Monga AK (eds): Clinical urogynaecology, 2nd edn. London, Churchill Livingstone, 2000, pp 487-520.
149. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. J Urogynaecol Pelv Floor Dysfunct 1998; 9: 100-2.
150. Yamamoto T, Honbo T, Tokoro K, et al. General pharmacology of the new antimuscarinic compound vamicamide. Ar-zeimittelforschungDrugsRes. 1995;45: 1274-84.
151. Yamanishi T, YasudaK, Homma Y, et al. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-block-er on neurogenic bladder dysfunction. Eur Urol 1999; 35:4551.
152. Yasuda K, Kawabe K, Takimoto Y, et al. A double-blind clinical trial of a beta-2 adrenergic agonist in stress incontinence. Int Urogynecol J 1993; 4:146-51.
153. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002; 168: 1897-1913.
154. Youdin K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 2002;59:428-32.
155. Zderic SA, Levin RM, Wein AJ. Voiding function: Relevant anatomy, physiology, pharmacology and molecular aspects. In: Gillenwater JY, Howards SS, Grayhack JT, Duckett JW (eds): Adult and pediatric urology, 3rd edn. Chicago, Mosby-Year Book, 1995, pp 1159-1219.
156. Zinner N, Gittelman M, Harris R et al. Trospium chloride improves bladder symptoms: A multicenter phase III trial. J Urol 2004; 171:2311-15.